GLP-1 Drugs Work — Keeping the Weight Off Takes Diet and Exercise

The weight-loss drugs reshaping American medicine have a quieter second act: what happens to the body while the number on the scale falls, and what happens after the prescriptions stop. A 2025 review in Frontiers in Clinical Diabetes and Healthcare argues both questions have the same answer — and it is not written on a prescription pad.

The review, by researchers Roberto Codella, Pamela Senesi and Livio Luzi, synthesized a decade of randomized trials and meta-analyses of GLP-1 receptor agonists — the drug class that includes semaglutide and liraglutide — in adults with obesity or type 2 diabetes. Its conclusion: the medications are the most effective obesity drugs yet developed, and they still work best as one half of a partnership with structured exercise and diet.

What the drugs deliver

The numbers explain the demand. Across trials, GLP-1 medications produced average losses of 7 to 9 kilograms — roughly 15 to 20 pounds — over about a year, with semaglutide reaching 10% to 15% of body weight or more and tirzepatide, a newer dual-hormone drug, exceeding that. For patients who have cycled through diets for decades, those are results medicine could not reliably offer before.

The muscle problem

The scale, however, does not say what kind of weight is leaving. In the trials the review examined, a meaningful share of the loss was lean mass — muscle — not fat. Roughly 25% of the weight lost on tirzepatide and about 22% on liraglutide came from lean mass; semaglutide showed the same pattern. Muscle is the body's metabolic engine and its insurance policy against frailty, so losing it alongside fat undercuts the very health gains the drugs are prescribed for — particularly in older adults.

The regain problem

The second catch arrives after the last injection. Patients who stopped the medication regained weight rapidly — up to two-thirds of what they had lost within a year of discontinuing, the review found. Appetite returns, and without new habits underneath it, so does the weight.

What exercise changes

The review's central finding is that pairing the drugs with structured exercise attacked both problems at once, with effects the authors describe as additive and, in places, synergistic: greater total weight loss, preserved muscle and steadier metabolic health over time. Resistance training — lifting, bands, bodyweight work — did the heavy lifting on muscle preservation, while a protein-adequate diet of smaller, nutrient-dense meals supported it. Patients who built those habits while on the medication kept more of their progress when it ended.

The takeaway

The authors' prescription for the field is a hybrid model: pharmacotherapy and lifestyle treated as one program rather than rivals. For patients, the practical version is unglamorous — strength training a few days a week, protein at every meal, vegetables and whole foods doing the daily work — started while the medication is doing its part, not after.

Eating that way takes planning, which is where tools like personalized nutrition earn their keep: knowing your own protein, calorie and micronutrient targets turns “eat better” into a shopping list.

This article is health education, not medical advice. GLP-1 medications are prescription drugs with real side effects and real benefits; decisions about starting, continuing or stopping them belong with you and your clinician.

Explore more guides on the Learn page, or get your free Health Report.